Navigation Links
High-dose fluticasone effective against eosinophilic esophagitis
Date:7/18/2014

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with EoE are steroid-resistant. By analyzing gene expressionthe degree to which certain genes are turned on or offin esophageal tissues, the scientists identified a cluster of genes that may help predict steroid responsiveness. The study, led by Marc Rothenberg, M.D., Ph.D., of Cincinnati Children's Hospital Medical Center and the University of Cincinnati, was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

EoE affects an estimated 1 in 2,500 people. Symptoms vary, and may include trouble swallowing and abdominal pain. Based on previous research by Dr. Rothenberg and others, physicians typically use oral fluticasone off-label to treat patients with EoE, but studies have shown that some patients do not respond to 880-microgram daily doses of the drug. In the current study, researchers evaluated the effectiveness of a higher dose in adults and children with EoE. For three months, 28 participants swallowed 1760 micrograms of fluticasone each day, while 14 received placebo. At the end of the three-month period, 65 percent of participants who took the drug were in complete remission, based on the near absence of eosinophils in their esophageal tissues, compared to none who took placebo. Those in remission were switched to 880 micrograms of daily fluticasone for an additional three months, and 93 percent remained in complete or partial remission. Participants who did not respond to fluticasone during the first three months received 1760-microgram doses for three more months, but remained largely unresponsive to the drug. The findings suggest that approximately 25 percent of people with EoE do not respond to steroid treatment.

The scientists also evaluated gene expression in esophageal tissue samples. They found that the gene expression signatures of participants who went into remission changed substantially, becoming similar but not identical to those of healthy people. The changes in signatures of participants who did not respond to fluticasone were small, suggesting that these participants were resistant to the drug. The investigators identified 15 genes that may be useful in identifying patients who will respond to steroid treatment, but further studies are needed to confirm this finding.


'/>"/>
Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Predicting outcome for high-dose IL-2 therapy in cancer patients
2. Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Associated Cancers by 62 Percent
3. High-Dose Statins Linked to Acute Kidney Damage
4. High-dose Vorinostat effective at treating relapsed lymphomas
5. Controlling spine metastases with tumor separation surgery and high-dose stereotactic radiosurgery
6. 4 lessons for effective, efficient research in health care settings
7. Depressed men with prostate cancer are diagnosed later stage, get less effective therapies
8. Non-diet approach to weight management more effective in worksite wellness programs
9. R.I. lead law effective, often ignored
10. Drug shows promise for effectively treating metabolic syndrome
11. Biomarker predicts effectiveness of brain cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... 2017 Tempus, a technology company focused ... Hospitals Seidman Cancer Center have joined together to ... advanced molecular analysis and clinical decision support tools ... providers. As part of the ... sequencing and analysis for ovarian and triple negative ...
Breaking Medicine Technology: